Table 1.
The Clinical Parameters of the Study Population
| Variables | Groups of Cycles According to the Quartiles of HOMA-IR | P-valuea | |||
|---|---|---|---|---|---|
| Q1 (<1.63) | Q2 (1.63–2.33) | Q3 (2.33–3.43) | Q4 (≥ 3.43) | ||
| Number | 1959 | 1959 | 1959 | 1959 | |
| Age (y) | 31.09 ± 3.70 | 30.35 ± 3.84 | 30.10 ± 3.83 | 29.55 ± 4.05 | <0.001 |
| BMI (kg/m2) | 21.68 ± 2.45 | 22.64 ± 2.70 | 23.91 ± 3.10 | 26.47 ± 3.71 | <0.001 |
| Infertile duration (y) | 3.47 ± 2.65 | 3.45 ± 2.56 | 3.59 ± 2.49 | 3.75 ± 2.62 | <0.001 |
| Primary infertility | 1009 (51.51%) | 1010 (51.56%) | 1057 (53.96%) | 1138 (58.09%) | <0.001 |
| Infertility factor | |||||
| PCOS | 205 (10.46%) | 288 (14.70%) | 356 (18.17%) | 592 (30.22%) | <0.001 |
| Tubal factor | 1030 (52.58%) | 1053 (53.75%) | 1003 (51.20%) | 875 (44.67%) | <0.001 |
| Male factor | 476 (24.30%) | 403 (20.57%) | 420 (21.44%) | 328 (16.74%) | <0.001 |
| Endometriosis | 96 (4.90%) | 88 (4.49%) | 69 (3.52%) | 47 (2.40%) | <0.001 |
| Uterine factor | 25 (1.28%) | 28 (1.43%) | 17 (0.87%) | 19 (0.97%) | 0.311 |
| Unexplained | 127 (6.48%) | 99 (5.05%) | 94 (4.80%) | 98 (5.00%) | 0.073 |
| AMH (ng/mL) | 4.24 ± 3.10 | 4.55 ± 3.32 | 4.52 ± 3.21 | 4.94 ± 3.44 | <0.001 |
| AFC | 14.67 ± 5.39 | 15.37 ± 5.70 | 15.94 ± 5.86 | 17.98 ± 6.19 | <0.001 |
| Base FSH (mIU/mL) | 6.54 ± 1.81 | 6.30 ± 1.72 | 6.17 ± 1.64 | 5.85 ± 1.53 | <0.001 |
| FINS (μU/mL) | 5.86 ± 1.47 | 9.35 ± 1.24 | 13.06 ± 1.82 | 23.32 ± 10.29 | <0.001 |
| FPG (mmol/l) | 4.61 ± 0.42 | 4.78 ± 0.44 | 4.89 ± 0.45 | 5.10 ± 0.51 | <0.001 |
| HOMA-IR | 1.20 ± 0.29 | 1.97 ± 0.21 | 2.82 ± 0.31 | 5.28 ± 2.48 | <0.001 |
| GnRH agonist protocol | 1606 (81.98%) | 1644 (83.92%) | 1618 (82.59%) | 1658 (84.64%) | 0.102 |
| Initial Gn dose (IU) | 152.09 ± 49.52 | 149.45 ± 45.06 | 154.06 ± 46.71 | 157.62 ± 46.67 | <0.001 |
| Total Gn dose (IU) | 2054.60 ± 804.41 | 2033.60 ± 797.21 | 2171.02 ± 884.05 | 2487.81 ± 1097.77 | <0.001 |
| Duration of Gn (d) | 10.83 ± 2.36 | 10.80 ± 2.47 | 11.03 ± 2.73 | 11.88 ± 3.16 | <0.001 |
| Dominant follicle count | 7.70 ± 3.81 | 7.66 ± 3.80 | 7.57 ± 4.00 | 7.68 ± 4.04 | 0.391 |
| Endometrium thickness (mm) | 11.11 ± 2.67 | 11.17 ± 2.68 | 11.19 ± 2.76 | 11.14 ± 2.70 | 0.912 |
| Retrieved oocytes | 12.53 ± 6.35 | 12.47 ± 6.61 | 12.16 ± 6.63 | 11.72 ± 6.53 | <0.001 |
| MII oocytes | 10.46 ± 5.65 | 10.44 ± 5.90 | 10.19 ± 5.89 | 9.80 ± 5.86 | <0.001 |
| No. of embryos | 6.20 ± 4.09 | 6.12 ± 4.18 | 6.04 ± 4.13 | 5.72 ± 4.07 | <0.001 |
| High-quality Embryos’ no. | 3.41 ± 2.96 | 3.40 ± 3.03 | 3.40 ± 3.03 | 3.22 ± 2.99 | 0.029 |
| OSI | 7.20 ± 5.08 | 7.25 ± 5.38 | 6.64 ± 4.99 | 5.68 ± 4.38 | <0.001 |
Note: aA two-tailed P-value < 0.05 was considered statistically significant.
Abbreviations: HOMA-IR, homeostatic model assessment of insulin resistance; BMI, body mass index; PCOS, polycystic ovary syndrome; AMH, anti-mullerian hormone; AFC, antral follicle count; FSH, follicle-stimulating hormone; FINS, fasting serum insulin; FPG, fasting plasma glucose; COH, controlled ovarian hyperstimulation; GnRH, gonadotropin-releasing hormone; Gn, gonadotropin; MII, metaphase II; OSI, ovarian sensitivity index.